Genomic view of IFN-α response in pre-autoimmune NZB/W and MRL/lpr mice

Genes and Immunity

Volumn 8, Issue 7, 2007, Pages 590-603

  Lu, Q ^a   Shen, N ^a   Li, X M ^a   Chen, S L ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ATM PROTEIN; BINDING PROTEIN; CALCYCLIN; CASPASE 3; CASPASE 4; CASPASE 8; CD69 ANTIGEN; CHEMOKINE; COLLAGENASE 3; CYCLIN D2; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYTOKINE; CYTOSKELETON PROTEIN; DAXX PROTEIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; HEMATOPOIETIC CELL KINASE; INTERLEUKIN 1BETA CONVERTING ENZYME; LIPOPROTEIN RECEPTOR; MEMBRANE RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE P38; MYC PROTEIN; MYELOID DIFFERENTIATION FACTOR 88; PARVALBUMIN; PROTEIN BCL 2; PROTEIN FOS; REGULATOR PROTEIN; SECURIN; SERINE PROTEINASE INHIBITOR;

ANIMAL CELL; APOPTOSIS; ARTICLE; AUTOIMMUNITY; CELL CYCLE REGULATION; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; GENE CONTROL; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENOMICS; IMMUNE RESPONSE; IMMUNOGENETICS; IMMUNOPATHOGENESIS; MITOSIS INHIBITION; MONONUCLEAR CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SPLEEN CELL; SYSTEMIC LUPUS ERYTHEMATOSUS; UNINDEXED SEQUENCE; UPREGULATION;

ANIMALS; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; INTERFERON TYPE I, RECOMBINANT; LEUKOCYTES, MONONUCLEAR; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED BALB C; MICE, INBRED MRL LPR; MICE, INBRED NZB; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION;

ATAXIA TELANGIECTASIA; MURINAE; MUS;

EID: 35548991048     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/sj.gene.6364421     Document Type: Article

References (59)

1. Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979; 301: 5-8.
2. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ et al. Interferon-inducible gene expression signattire in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003; 100: 2610-2615.
3. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003; 197: 711-723.
4. Han GM, Chen SL, Shen N, Ye S, Bao CD, Gu YY. Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray. Genes Immun 2003; 4: 177-186.
5. Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 2005; 52: 1491-1503.
6. Crow MK, Kirou KA, Wohlgemuth J. Microarray analysis of interferon-regulated genes in SLE. Autoimmunity 2003; 36: 481-490.
7. Santiago-Raber ML, Baccala R, Haraldsson KM, Choubey D, Stewart TA, Kono DH et al. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 2003; 197: 777-788.
8. 1 but not in BALB/c mice. J Immunol 2005; 174 2499-2506.
9. Hron JD, Peng SL. Type I IFN protects against murine lupus. J Immunol 2004; 173: 2134-2142.
10. lpr mice. J Am Soc Nephrol 2005; 16: 3264-3272.
11. Hadj-Slimane R, Chelbi-Alix MK, Tovey MG, Bobe P. An essential role for IFN-α in the overexpression of Fas ligand on MRL/lpr lymphocytes and on their spontaneous Fas-mediated cytotoxic potential. J Interferon Cytokine Res 2004; 24: 717-728.
12. Watanabe-Fukunaga F, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992; 356: 314-317.
13. Ronnblom LE, Alm GV, Oberg K. Autoimmune phenomena in patients with malignant carcinoid tumors during interferon-alpha treatment. Acta Oncol 1991; 30: 537-540.
14. Niewold TB, Swedler WI. Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C. Clin Rheumatol 2005; 24: 178-181.
15. Wandl UB, Nagel-Hiemke M, May D, Kreuzfelder E, Kloke O, Kranzhoff M et al. Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders. Clin Immunol Immunopathol 1992; 65: 70-74.
16. Hahn BH. Animal models of systemic lupus erythematosus. In: Wallace DJ, Hahn BH (eds). Dubois' Lupus Erythematosus, 6th edn. Lippincott Williams and Wilkins: Philadelphia, 2002, pp 339-388.
17. Theofilopoulos AN. Murine models of lupus. In: Lahita RG (eds). Systemic Lupus Erythematosus. Churchill Livingston: New York, 1992, pp 121.
18. Sharif MN, Tassiulas I, Hu Y, Mecklenbrauker I, Tarakhovsky A, Ivashkiv LB. IFN-α priming results in a gain of proinflammatory function by IL-10: Implications for systemic lupus erythematosus pathogenesis. J Immunol 2004; 172: 6476-6481.
19. Dorner BG, Scheffold A, Rolph MS, Hüser MB, Kaufmann SHE, Radbruch A et al. MIP-1α, MIP-1β, RANTES, and ATAC/lymphotactin function together with IFN-γ as type 1 cytokines. Proc Natl Acad Sci USA 2002; 99: 6181-6186.
20. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev 1998; 12: 2245-2262.
21. Hamid T, Kakar SS. PTTG/securing activates expression of p53 and modulates its function. Mol Cancer 2004; 3: 18.
22. Yu R, Heaney AP, Lu W, Chen J, Melmed S. Pituitary tumor transforming gene causes aneuploidy and p53-dependent and p53-independent apoptosis. J Biol Chem 2000; 275: 36502-36505.
23. Pusapati RV, Rounbehler RJ, Hong S, Powers JT, Yan M, Kiguchi K et al. ATM promotes apoptosis and suppresses tumorigenesis in response to Myc. Proc Natl Acad Sci USA 2006; 103: 1446-1451.
24. Fukushima T, Zapata JM, Singha NC, Thomas M, Kress CL, Krajewska M et al. Critical function for SIP, a ubiquitin E3 ligase component of the beta-catenin degradation pathway, for thymocyte development and G1 checkpoint. Immunity 2006; 24: 29-39.
25. 1 arrest and apoptosis. Cancer Res 1994; 54: 1169-1174.
26. 1 phase arrest through up-regulated expression of CDK inhibitors, p19Ink4D and p21Cip1 in mouse macrophage. Oncogene 1998; 16: 2075-2086.
27. Zhan Q, Antinore MJ, Wang XW, Carrier F, Smith ML, Harris CC et al. Association with Cdc2 and inhibition of Cdc2/Cyclin B1 kinase activity by the p53-regulated protein Gadd45. Oncogene 1999; 18 2892-2900.
28. Santiago-Raber ML, Lawson BR, Dummer W, Barnhouseb M, Koundouris S, Wilson CB et al. Role of cyclin kinase inhibitor p21 in systemic autoimmunity. J Immunol 2001; 167: 4067-4074.
29. Goulvestre C, Chereau C, Nicco C, Mouthon L, Weill B, Batteux F. A mimic of p21WAF1/CIP1 ameliorates murine lupus. J Immunol 2005; 175 6959-6967.
30. Liu L, Tran E, Zhao YN, Huang YC, Flavell R, Lu BF. Gadd45β and Gadd45γ are critical for regulating autoimmunity. J Exp Med 2005; 202: 1341-1347.
31. Waldmann TA. Targeting the interleukin-15/interleukin-15 receptor system in inflammatory autoimmune diseases. Arthritis Res Ther 2004; 6 174-177.
32. Moon JJ, Rubio ED, Martino A, Krumm A, Nelson BH. Permissive role for phosphatidylinositol 3-kinase in the Stat5-mediated expression of cyclin D2 by the interleukin-2 receptor. J Biol Chem 2004; 279: 5520-5527.
33. Konttinen YT, Ainola M, Valleala H, Ma J, Ida H, Mandelin J et al. Analysis of 16 different matrix metalloproteinases (MMP-1-MMP-20) in the synovial membrane: Different profiles in trauma and rheumatoid arthritis. Ann Rheum Dis 1999; 58: 691-697.
34. Yahata T, de Caestecker MP, Lechleider RJ, Andriole S, Roberts AB, Isselbacher KJ et al. The MSG1 non-DNA-binding transactivator binds to the p300/CBP coactivators, enhancing their functional link to the Smad transcription factors. J Biol Chem 2000; 275: 8825-8834.
35. Bhattacharya S, Eckner R, Grossman S, Oldread E, Arany Z, d'Eckner A et al. Cooperation of Stat2 and p300/CBP in signaling induced by interferon-a. Nature 1996; 383: 344-347.
36. Sancho D, Gomez M, Viedma F, Esplugues E, Gordon-Alonso M, Garcia-Lopez MA et al. CD69 downregulates autoimmune reactivity through active transforming growth factor-β production in collagen-induced arthritis. J Clin Invest 2003; 112: 872-882.
37. Zhang H, Meng F, Chu CL, Takai T, Lowell CA. The Src family kinases Hck and Fgr negatively regulate neutrophil and dendritic cell chemokine signaling via PIR-B. Immunity 2005; 22: 235-246.
38. JØrgensen TN, Gubbels MR, Kotzin BL, Links between type I interferon and the genetic basis of disease in mouse lupus. Autoimmunity 2003; 36: 491-502.
39. Vyse TJ, Drake CG, Rozzo SJ, Roper E, Izui S, Kotzin BL. Genetic linkage of IgG autoantibody production in relation to lupus nephritis in New Zealand hybrid mice. J Clin Invest 1996; 98: 1762-1772.
40. Morel L, Rudofsky UH, Longmate JA, Schiffenbauer J, Wakeland EK. Polygenic control of susceptibility to murine systemic lupus erythematosus. Immunity 1994; 1: 219-229.
41. Mohan C, Alas E, Morel L, Yang P, Wakeland EK. Genetic dissection of SLE pathogenesis Sle 1 on murine chromosome 1 leads to a selective loss of tolerance to H2A/H2B/DNA subnucleosomes. J Clin Invest 1998; 101: 1362-1372.
42. Kono DH, Burlingame RW, Owens DG, Kuramochi A, Balderas RS, Balomenos D et al. Lupus susceptibility loci in New Zealand mice. Proc Natl Acad Sci USA 1994; 91: 10168-10172.
43. Kawai T, Takeuchi O, Fujita T, Inoue JI, Mühlradt PF, Sato S et al. Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J Immunol 2001; 167: 5887-5894.
44. Toshchakov V, Jones BW, Perera. PY, Thomas K, Cody MJ, Zhang S et al. TLR4, but not TLR2, mediates IFN-β-induced STAT1a/β-dependent gene expression in macrophages. Nat Immunol 2002; 3: 392-398.
45. Wu C, Ohmori Y, Bandyopadhyay S, Sen G, Hamilton T. Interferon-stimulated response element and NFB sites cooperate to regulate double-stranded RNA-induced transc. J Interferon Res 1994; 6: 357-363.
46. Nakaya T, Sato M, Hata N, Asagiri M, Suemori H, Noguchi S et al. Gene induction pathways mediated by distinct IRFs during viral infection. Biochem Biophys Res Commun 2001; 283: 1150-1156.
47. Gresser I. Vignaux F, Belardelli F, Tovey MG, Maunoury MT. Injection of mice with antibody to mouse interferon γ/β decreases the level of 2′-5′ oligoadenylate synthetase in peritoneal macrophages. J Virol 1985; 53: 221-227.
48. Qian L, Liu Y, Sun HB, Yokota H. Systems analysis of matrix metalloproteinase mRNA expression in skeletal tissues. Front Biosci 2002; 7: A126-a134.
49. Li WQ, Dehnade F, Zafarullah M. Oncostatin M-induced matrix metalloproteinase and tissue inhibitor of metalloproteinase-3 genes expression in chondrocytes requires Janus kinase/STAT signaling pathway. J Immunol 2001; 166: 3491-3498.
50. Sun HB, Zhu YX, Yin T, Sledge G, Yang YC. MRG1, the product of a melanocyte-specific gene related gene, is a cytokine-inducible transcriptiqn factor with transformation activity. Proc Natl Acad Sci USA 1998; 95: 13555-13560.
51. Leung MK, Jones T, Michels CL, Livingston DM, Bhattacharya, S, Molecular cloning and chromosomal localization of the human CITED2 gene encoding p35srj/Mrgl: Genomics 1999; 61: 307-313.
52. Tien ES, Davis JW, Vanden Heuvel JP. Identification of the CREB-binding protein/p300-interacting protein CITED2 as a peroxisome proliferator-activated receptor a coregulate. J Biol. Chem 2004; 279: 24053-24063.
53. Delerive P, Fruchat JC, Staels B. Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 2001; 169: 453-459.
54. Zhu M, John S, Berg M, Leonard WJ. Functional association of Nmi with Stat5 and Stat1 in IL-2- and IFNgamma-mediated signaling. Cell 1999; 96: 121-130.
55. Bauer JW, Baechler EC, Petri M, Batliwalla FM, Crawford D, Ortmann WA et al. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med 2006; 3: 2274-2284.
56. Loetscher M, Gerber B, Loetscher P, Jones SA, Piali L, Clark-Lewis I et al. Chemokine receptor specific for IP10 and Mig: Structure, function, and expression in activated T-lymphocytes. J Exp Med 1996; 184: 963-969.
57. Elbourne KB, Keisler D, McMurray RW. Differential effects of estrogen and prolactin on autoimmune disease in the NZB/W mouse Model of SLE. Lupus 1998; 7: 420-427.
58. McMurray R, Keisler D, Kanuckel K, Izui, S, Walker S. Prolactin influences autoimmune disease activity in the female NZB/W mouse. J Immunol 1991; 147: 3780-3787.
59. Horwitz GA, Miklovsky I, Heaney AP, Ren SG, Melmed S. Human pituitary tumor-transforming gene (PITG1) motif suppresses prolactin expression. Mol Endocrinol 2003; 17: 600-609